Abstract
A transdermal formulation of buprenorphine was introduced in 2001, which reignited interest in this medication for the treatment of chronic moderate-to-severe pain. This review presents the evidence published since November 2011, focusing on issues of safety and efficacy, and providing evidence-based guidance on clinical applications of transdermal buprenorphine. Medical literature were identified by searching databases, including Medline, EMBASE, PsychINFO, AMED, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, the Cochrane Methodology Register, the Health Technology Assessment, and the NHS Economic Evaluation Database. All randomized controlled trials in adults diagnosed with chronic non-malignant moderate-to-severe pain were included.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
